| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.0073 | 0.9 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.9 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | -0.024 | 0.9 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.9 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |